

CTC Promising As Adjunct to Colonoscopy

BY DAMIAN McNAMARA

ORLANDO — CT colonography continues to show promise as an adjunct to colonoscopy for colorectal cancer screening, according to study findings.

Dr. Ruben D. Acosta and his associates assessed 170 average-risk patients at the National Naval Medical Center in Bethesda, Md. All patients had computed tomographic colonography (CTC) followed by a colonoscopy. Polyp histology was used to compare results from 92 participants with a positive CTC and another 60 randomly selected patients with a negative CTC. Mean age was 56 years, 32% were women, and 82% were white.

In previous studies, the researchers had demonstrated that CTC could detect polyps 6 mm or larger as accurately as colonoscopy on a per-patient basis (*Gastroenterology* 2006;130:A46).

In the current study, the histology showed that 6 of the 60 patients with a negative CTC had adenoma and 2 had advanced adenoma. In addition, 58% of patients with a normal CTC had at least one polyp detected on colonoscopy, Dr. Acosta said at the annual meeting of the American College of Gastroenterology.

"This underscores the complementary relationship between CTC and colonoscopy programs," said Dr. Acosta, a gastroenterologist at the center.

Of the 348 polyps detected by colonoscopy, 59% were smaller than 6 mm, 26% were 7-9 mm, and 15% were 10 mm or larger. Histology suggested that 167 of these polyps were adenomas (48%). A total of 76, or 46%, of these polyps were noted on the initial CTC report.

However, CTC missed 222 polyps detected by colonoscopy, including 87 hyperplastic polyps and 84 adenomas. In addition, CTC missed seven advanced adenomas (an overall 3% miss rate).

Two of the seven advanced adenomas missed by CTC were smaller than 10 mm (a 0.9% miss rate).

The miss rate for CTC was inversely associated with polyp size, Dr. Acosta said. As expected, 79% of the 222 polyps missed by CTC, but detected by follow-up colonoscopy, were smaller than 6 mm.

Among the 16% of missed polyps in the 7-mm to 9-mm range, 15 polyps were hyperplastic and 17 were adenomas. The remaining polyps that were missed by CTC were 10 mm or larger and included five hyperplastic polyps and five adenomas.

The CTC miss rate for polyps greater than 10 mm was 4.5%. Dr. Acosta said this miss rate is comparable to the rate of large polyps missed with tandem colonoscopy (*Am. J. Gastroenterol.* 2006;101:343-50). In this systematic review of six studies with 465 patients, researchers found a 2.1% miss rate for polyps 10 mm or larger.

Dr. Acosta reported having no disclosures related to his presentation. ■

FOB Tests Useful in Colon Ca Screening

BY MICHAEL VLESSIDES

BANFF, ALTA. — A colorectal screening program in Ontario has proven successful in detecting high-risk adenomas and colorectal cancer in patients referred because of positive fecal occult blood test results or a family history of colorectal cancer.

"About 2 years ago, the Ontario Ministry of Health announced this new colorectal screening program, which is

based on fecal occult blood [FOB] testing for average-risk patients and colonoscopy for those with a first-degree relative with colorectal cancer," said Dr. William G. Paterson at the Canadian Digestive Diseases Week. "And certainly amongst the GI community there was controversy as to whether a screening program based on FOB testing was the best approach," he added.

To answer this question, Dr. Paterson and his colleagues reviewed the charts

of 764 patients referred to the program; 122 were referred because of positive FOB tests. Of those, 14 patients were found to have cancer (11.4% diagnostic yield) and 30 had high-risk adenomas (24.6% diagnostic yield).

The remaining 642 patients screened through the program had a family history of colorectal cancer. Eleven cases of cancer (1.7% diagnostic yield) and 37 high-risk adenomas (5.8% diagnostic yield) were found. The yield for this co-



IMPORTANT TREATMENT CONSIDERATIONS

PRISTIQ 50-mg Extended-Release Tablets are indicated for the treatment of major depressive disorder in adults.

WARNING: SUICIDALITY AND ANTIDEPRESSANT DRUGS

Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of Major Depressive Disorder (MDD) and other psychiatric disorders. Anyone considering the use of PRISTIQ or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. PRISTIQ is not approved for use in pediatric patients.

Contraindications

- PRISTIQ is contraindicated in patients with a known hypersensitivity to PRISTIQ or venlafaxine.
- PRISTIQ must not be used concomitantly with an MAOI or within 14 days of stopping an MAOI. Allow 7 days after stopping PRISTIQ before starting an MAOI.

Warnings and Precautions

- All patients treated with antidepressants should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of treatment and when changing the dose. Consider changing the therapeutic regimen, including possibly discontinuing the medication, in patients whose depression is persistently worse or includes symptoms of anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia, hypomania, mania, or suicidality that are severe, abrupt in onset, or were not part of the patient's presenting symptoms. Families and caregivers of patients being treated with antidepressants should be alerted about the need to monitor patients.
- Development of a potentially life-threatening serotonin syndrome may occur with SNRIs and SSRIs, including PRISTIQ, particularly with concomitant use of serotonergic drugs, including triptans, and with drugs that impair the metabolism of serotonin (including MAOIs). If concomitant use is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases. Concomitant use of PRISTIQ with serotonin precursors is not recommended.
- Patients receiving PRISTIQ should have regular monitoring of blood pressure since sustained increases in blood pressure were observed in clinical studies. Pre-existing hypertension should be controlled before starting PRISTIQ. Caution should be exercised in treating patients with pre-existing hypertension or other underlying conditions that might be compromised by increases in blood pressure. Cases of elevated blood pressure requiring immediate treatment have been reported. For patients who experience a sustained increase in blood pressure, either dose reduction or discontinuation should be considered.